Osteoporosis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Osteoporosis Treatment Market Size & Share. The Market is Segmented by Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types), Application (Primary Osteoporosis and Secondary Osteoporosis), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD Million) for all the Above Segments.

Osteoporosis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Osteoporosis Drugs Market Size

Osteoporosis Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 16.88 Billion
Market Size (2030) USD 21.28 Billion
CAGR (2025 - 2030) 4.74 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Osteoporosis Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Osteoporosis Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Osteoporosis Drugs Market Analysis

The Osteoporosis Drugs Market size is estimated at USD 16.88 billion in 2025, and is expected to reach USD 21.28 billion by 2030, at a CAGR of 4.74% during the forecast period (2025-2030).

The rising prevalence of osteoporosis, along with the growing geriatric population and fragility fractures, is expected to drive demand for effective treatment solutions. These demographic and health trends are anticipated to significantly contribute to the expansion of the osteoporosis drugs market. For instance, according to a report published in the Archives of Osteoporosis Journal in April 2024, the prevalence of osteoporosis is rising, showing a prevalence of 15.9% in individuals aged 50 and over, with a significant gender disparity. Many osteoporosis-related fractures remain undiagnosed, and only 30% of diagnosed individuals receive proper treatment, especially with a pronounced treatment gap in men. This increasing need for diagnosis and treatment directly fuels demand for osteoporosis drugs, driving market growth.

Furthermore, spinal cord injuries are associated with the development of osteoporosis. For instance, according to a report published in the BMC Medicine Journal in July 2024, the rising incidence of spinal cord injuries, with an overall incidence rate of 23.77 per million people, leads to increased mobility challenges and a higher risk of bone-related complications. As individuals with spinal cord injuries are prone to developing osteoporosis due to prolonged immobility, the need for effective therapeutic interventions is becoming more urgent. This growing demand for osteoporosis management solutions is propelling the expansion of the osteoporosis drugs market.

Additionally, the rising launches and approvals by the market players are expected to boost the market growth during the forecast period. For instance, in November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., received approval for a generic version of Forteo in the U.S. market. The teriparatide injection is indicated for the treatment of osteoporosis in select women and men. Similarly, in August 2022, the Ministry of Health, Labour, and Welfare (MHLW) approved the Edirol Tablet by Towa Pharmaceutical in Japan. Introducing new generic formulations and approvals of osteoporosis treatments enhances market accessibility and provides more therapeutic options, driving the growth of the osteoporosis drugs market by addressing unmet clinical needs.

In conclusion, the growth of the osteoporosis drugs market is driven by increasing incidences of osteoporosis, rising demand for effective treatments due to related fractures and injuries, and the introduction of new therapeutic formulations and approvals.

However, stringent approval and marketing regulations are expected to restrain the market growth.

Osteoporosis Drugs Industry Overview

The osteoporosis drugs market is competitive and consists of several major players. Some of the companies currently dominating the market are Amgen Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., and Pfizer Inc.

Osteoporosis Drugs Market Leaders

  1. Amgen Inc.

  2. Eli Lily and Company

  3. F. Hoffmann La Roche

  4. Merck & Co. Inc.

  5. Pfizer Inc

  6. *Disclaimer: Major Players sorted in no particular order
Osteoporosis Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Osteoporosis Drugs Market News

  • September 2024: The National Institute for Health and Care Excellence (NICE) in the UK approved abaloparatide, a potent anabolic therapy, for patients at elevated fracture risk, marking a significant advancement in osteoporosis treatment. Abaloparatide is gaining momentum in the global osteoporosis market due to its proven efficacy and increasing acceptance among healthcare professionals.
  • March 2024: The FDA approved two interchangeable biosimilars: Jubbonti (denosumab-bbdz) injection for the U.S.-licensed Prolia (denosumab) and Wyost (denosumab-bbdz) injection for the U.S.-licensed Xgeva (denosumab), respectively. These products inhibit the RANKL/RANK interaction, preventing osteoclast-mediated bone degradation, and represent the one of the first interchangeable biosimilar for a RANKL inhibitor.

Osteoporosis Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Incidence of Osteoporosis
    • 4.2.2 Rise in the Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Stringent Approval and Marketing Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - in USD)

  • 5.1 By Drug Type
    • 5.1.1 Parathyroid Hormone Therapy
    • 5.1.2 Bisphosphonates
    • 5.1.3 Calcitonin
    • 5.1.4 RANKL Inhibitors
    • 5.1.5 Other Drug Types
  • 5.2 By Application
    • 5.2.1 Primary Osteoporosis
    • 5.2.2 Secondary Osteoporosis
  • 5.3 Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Injectable
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 Eli Lily and Company
    • 6.1.3 F. Hoffmann La Roche
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 Novartis International AG
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Radius Health Inc.
    • 6.1.9 Strides Pharma Science Limited
    • 6.1.10 Teva Pharmaceutical Industries Ltd
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Osteoporosis Drugs Industry Segmentation

As per the report's scope, osteoporosis drugs are pharmacological agents designed to prevent bone loss, enhance bone density, and reduce the risk of fractures in individuals with weakened skeletal structures due to reduced bone mass. These drugs typically work by either inhibiting bone resorption or stimulating bone formation, offering therapeutic solutions to manage and treat osteoporosis. The osteoporosis drugs market is segmented by drug type, application, and geography. The drug type is further divided into parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL Inhibitors, and other drug types. The application segment is further segmented into primary osteoporosis and secondary osteoporosis. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecast in value (USD) for the above segments.

By Drug Type Parathyroid Hormone Therapy
Bisphosphonates
Calcitonin
RANKL Inhibitors
Other Drug Types
By Application Primary Osteoporosis
Secondary Osteoporosis
Route of Administration Oral
Injectable
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Osteoporosis Drugs Market Research FAQs

How big is the Osteoporosis Drugs Market?

The Osteoporosis Drugs Market size is expected to reach USD 16.88 billion in 2025 and grow at a CAGR of 4.74% to reach USD 21.28 billion by 2030.

What is the current Osteoporosis Drugs Market size?

In 2025, the Osteoporosis Drugs Market size is expected to reach USD 16.88 billion.

Who are the key players in Osteoporosis Drugs Market?

Amgen Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc. and Pfizer Inc are the major companies operating in the Osteoporosis Drugs Market.

Which is the fastest growing region in Osteoporosis Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Osteoporosis Drugs Market?

In 2025, the North America accounts for the largest market share in Osteoporosis Drugs Market.

What years does this Osteoporosis Drugs Market cover, and what was the market size in 2024?

In 2024, the Osteoporosis Drugs Market size was estimated at USD 16.08 billion. The report covers the Osteoporosis Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Osteoporosis Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Osteoporosis Treatment Industry Report

The global osteoporosis drugs market is on the rise, propelled by medical advancements and an increasing elderly population susceptible to osteoporosis. Innovation in drug development is robust, particularly with new treatments like unique-cell based approaches and prostacyclin analogs. Key segments such as bisphosphonates and SGC stimulators are gaining traction for their potential in treating cardiopulmonary conditions. Oral medications remain preferred due to ease of administration, with growing interest in anabolic agents for patients at high risk of fractures. North America leads the market, supported by strong healthcare policies and infrastructure that facilitate the swift adoption of new treatments. Technological advancements in bone density scanning and drug delivery are improving treatment outcomes, with a notable shift towards biologic therapies and fracture prevention. Additionally, the integration of AI in drug development is enhancing personalization and efficacy in treatments. For further insights and a comprehensive market forecast, a detailed analysis is available for free download from Mordor Intelligence™.